Marshall Wace’s Benitec Biopharma BNTC Stock Holding History

Marshall Wace’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-71,832	Closed	-$765K	–	3186
2026 Q1	$765K	Buy	71,832 +36,144	+101%	+$418K	﹤0.01%	2258
2025 Q4	$481K	Buy	+35,688	New	+$494K	﹤0.01%	2252
2025 Q3	–	Sell	-43,003	Closed	-$503K	–	2910
2025 Q2	$503K	Buy	+43,003	New	+$602K	﹤0.01%	2140

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Marshall Wace's BNTC Position: Q2 2026 in Review

Marshall Wace sold out of Benitec Biopharma (BNTC) in Q2 2026, closing a stake of 71,832 shares — an estimated $765K sold.

Marshall Wace first reported a position in BNTC in Q2 2025 and held it in 3 quarters. The position peaked at $765K in Q1 2026. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Marshall Wace reported no remaining Benitec Biopharma position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 71,832 Benitec Biopharma shares in Q2 2026, an estimated $765K.
Marshall Wace first reported a position in Benitec Biopharma in Q2 2025 and held it in 3 quarters.
Marshall Wace's Benitec Biopharma position peaked at $765K in Q1 2026.
86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.